Abdel-Rehim M, Bielenstein M, Askemark Y, Tyrefors N, Arvidsson T
AstraZeneca R&D, Bioanalysical Chemistry, Södertälie, Sweden.
J Chromatogr B Biomed Sci Appl. 2000 May 12;741(2):175-88. doi: 10.1016/s0378-4347(00)00054-2.
A sensitive, selective and accurate high-performance liquid chromatographic-tandem mass spectrometric assay was developed and validated for the determination of lidocaine and its metabolites 2,6-dimethylaniline (2,6-xylidine), monoethylglycinexylidide and glycinexylidide in human plasma and urine. A simple sample preparation technique was used for plasma samples. The plasma samples were ultrafiltered after acidification with phosphoric acid and the ultrafiltrate was directly injected into the LC system. For urine samples, solid-phase extraction discs (C(18)) were used as sample preparation. The limit of quantification (LOQ) was improved by at least 10 times compared to the methods described in the literature. The LOQ was in the range 1.6-5 nmol/l for the studied compounds in plasma samples.